Lupin has allotted 5,893 equity shares under ESOP on 20 September 2024. Post allotment, the issued and paid-up capital of the Company has been increased to Rs 91,22,86,624 consisting of 45,61,43,312 equity shares of Rs 2/- each.Powered by Capital Market - Live

Vonoprazan is a novel potassium-competitive acid blocker (P-CAB). Unlike traditional acid suppressants like PPIs, Vonoprazan offers unique attributes like complete proton pump inhibition with the first dose, longer duration of action resulting in effective control of nocturnal acid breakthrough and meal-independent dosing. In India, Vonoprazan is approved by the Drug Controller General of India (DCGI) for treating reflux esophagitis, gastric ulcers, duodenal ulcers, and as part of Helicobacter pylori eradication treatment. The said drug will be marketed under the brand name Lupin's Lupivon and will be available in two strengths 10 mg and 20 mg. Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India. Rajeev Sibal, president India region formulations, Lupin,We are very pleased to commercialize Vonoprazan, a novel treatment option for Acid Peptic Disorders. This is a further step in strengthening our gastroenterology portfolio and is in line with our commitment to introduce innovative medicines to address unmet needs of our patients.' Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The company's consolidated net profit jumped 76.01% to Rs 801.31 crore during the quarter as compared with Rs 452.26 crore posted in Q1 FY24. Revenue from operations increased 16.28% YoY to Rs 5,514.34 crore during the quarter. The scrip declined 2.32% to Rs 2,217.85Powered by Capital Market - Live

Lupin announced that it has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company (Takeda), to commercialize Vonoprazan Tablets in the Indian market. The drug will be marketed under the brand name Lupin's Lupivon' and will be available in two strengths - 10 mg and 20 mg. Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India. Powered by Capital Market - Live

Lupin Ltd rose for a third straight session today. The stock is quoting at Rs 2308.6, up 1.38% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.06% on the day, quoting at 25182.65. The Sensex is at 82274.5, down 0.09%. Lupin Ltd has added around 20.82% in last one month. Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has added around 8.25% in last one month and is currently quoting at 23184.4, up 0.68% on the day. The volume in the stock stood at 10.3 lakh shares today, compared to the daily average of 18.32 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 2309.25, up 0.88% on the day. Lupin Ltd is up 102.68% in last one year as compared to a 28.41% gain in NIFTY and a 52.01% gain in the Nifty Pharma index.The PE of the stock is 37.93 based on TTM earnings ending June 24.Powered by Capital Market - Live

Mirabegron extended-release tablets are used to treat the symptoms of an overactive bladder (OAB), such as incontinence (loss of bladder control), a strong need to urinate right away, or a frequent need to urinate. It is also used to treat neurogenic detrusor overactivity (NDO). The said drug is a generic equivalent of Myrbetriq extended-release tablets of Astellas Pharma Global Development, Inc. As per IQVIA MAT July 2024, Mirabegron extended-release tablets had estimated annual sales of $1,600 million in the U.S. Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The company's consolidated net profit jumped 76.01% to Rs 801.31 crore during the quarter as compared with Rs 452.26 crore posted in Q1 FY24. Revenue from operations increased 16.28% YoY to Rs 5,514.34 crore during the quarter. The scrip hit an all time high of Rs 2,280.95 in intraday today. Powered by Capital Market - Live

 Lupin announced the launch of Mirabegron Extended-Release Tablets, 50 mg, in the United States, after having received an approval from the United States Food and Drug Administration (U.S. FDA). Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq' Extended-Release Tablets, 50 mg of Astellas Pharma Global Development, Inc. Mirabegron Extended-Release Tablets, 50 mg had estimated annual sales of USD 1,600 million in the U.S. (IQVIA MAT July 2024). Powered by Capital Market - Live

Lupin has allotted 1,21,150 fully paid-up equity shares of Rs 2 each under ESOP on 28 August 2024. With this allotment, the paid up equity share capital has increased to Rs 91,22,74,838 consisting of 45,61,37,419 equity shares of Rs 2/- each.Powered by Capital Market - Live

Lupin Ltd is up for a third straight session today. The stock is quoting at Rs 2214.9, up 2% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.31% on the day, quoting at 25094.85. The Sensex is at 81939.19, up 0.28%. Lupin Ltd has gained around 19.01% in last one month. Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has gained around 5.53% in last one month and is currently quoting at 22729, up 0.64% on the day. The volume in the stock stood at 7.47 lakh shares today, compared to the daily average of 18.96 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 2213.7, up 2.19% on the day. Lupin Ltd is up 101.78% in last one year as compared to a 29.74% jump in NIFTY and a 51.27% jump in the Nifty Pharma index.The PE of the stock is 36.17 based on TTM earnings ending June 24.Powered by Capital Market - Live

The benchmark indices continued to trade with strong gains in mid-morning trade. The Nifty traded above the 24,200 level. Metal shares advanced for the second consecutive trading session. At 11:30 IST, the barometer index, the S&P BSE Sensex, was up 635.69 points or 0.81% to 79,228.76. The Nifty 50 index gained 231.20 points or 0.96% to 24,223.75. The broader market outperformed the headline indices. The S&P BSE Mid-Cap index added 1.68% and the S&P BSE Small-Cap index gained 1.52%. The market breadth was strong. On the BSE, 2,786 shares rose and 944 shares fell. A total of 130 shares were unchanged. The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, tanked 9.05% to 17.05. IPO Update: The initial public offer (IPO) of Brainbees Solutions received 79,58,848 bids for shares as against 4,96,39,004 shares on offer, according to stock exchange data at 11:15 IST on Tuesday (06 August 2024). The issue was subscribed 0.16 times. The issue opened for bidding on Tuesday (06 August 2024) and it will close on Thursday (08 August 2024). The price band of the IPO is fixed between Rs 440 to Rs 465 per share. An investor can bid for a minimum of 32 equity shares and in multiples thereof. The initial public offer (IPO) of Unicommerce eSolutions received 6,15,71,184 bids for shares as against 1,40,84,681 shares on offer, according to stock exchange data at 11:15 IST on Tuesday (06 August 2024). The issue was subscribed 4.37 times. The issue opened for bidding on Tuesday (06 August 2024) and it will close on Thursday (08 August 2024). The price band of the IPO is fixed between Rs 102 to Rs 108 per share. An investor can bid for a minimum of 138 equity shares and in multiples thereof. Buzzing Index : The Nifty Metal index gained 2.12% to 9,077.15. The index advanced 1.82% in two consecutive trading sessions. Vedanta (up 4.31%), Jindal Stainless (up 3.93%), National Aluminium Company (up 3.23%), Steel Authority of India (up 2.98%) and JSW Steel (up 2.78%), Hindalco Industries (up 2.47%), Welspun Corp (up 2.47%), Adani Enterprises (up 2.37%), Hindustan Copper (up 2.34%) and NMDC (up 2.09%) advanced. Stocks in Spotlight : Lupin jumped 4.93% after the company's consolidated net profit jumped 76.01% to Rs 801.31 crore during the quarter as compared with Rs 452.26 crore posted in Q1 FY24. Revenue from operations increased 16.28% YoY to Rs 5,514.34 crore during the quarter. Tata Power Company fell 2.02% after the company's consolidated net profit decreased marginally to Rs 970.91 crore in Q1 FY25 as compared with Rs 972.49 crore in Q1 FY24. Revenue from operations grew 13.67% to Rs 17,293.62 crore during the first quarter as compared with Rs 15,213.29 crore in the corresponding quarter last year. Global Markets : Asian stocks advanced on Wednesday, recovering from sharp losses earlier in the week. Japan's markets surged following encouraging comments on interest rates from the Bank of Japan. However, lingering concerns about a global economic slowdown tempered overall sentiment. Bank of Japan (BoJ) Deputy Governor Shinichi Uchida said on Wednesday the central bank won't raise interest rates when financial markets are unstable. Regional markets drew support from a strong Wall Street close, though the U.S. recovery remained fragile after Monday's steep decline. Recent comments from Federal Reserve officials alleviated immediate recession fears, boosting investor confidence. The S&P 500 and Nasdaq rallied 1% on Tuesday, erasing some of the previous day's losses. The Fed has indicated that interest rate cuts might be necessary to prevent a recession, indicating a cautious outlook. The Dow Jones Industrial Average gained 294.39 points to close at 38,997.66, while the S&P 500 rose 53.7 points to 5,240.03. The Nasdaq Composite added 166.77 points, ending at 16,366.86. Powered by Capital Market - Live

Revenue from operations increased 16.28% YoY to Rs 5,514.34 crore during the quarter. Profit before tax (PBT) jumped 77.71% YoY to Rs 993.03 crore during the quarter. During the quarter, EBITDA jumped to Rs 1,308.8 crore as compared with Rs 879.1 crore posted in corresponding quarter last year, registering the growth of 48.9%. EBITDA margin was at 23.7% in Q1 FY25 as against 18.5% in Q1 FY24. Revenue from North America for Q1 FY2025 increased 28.3% to Rs 1,590.5 crore compared with Rs 1,900.6 crore in Q1 FY24, accounting for 37% of Lupin's global sales. In U.S. Q1 FY2025 sales were $227 Million as compared with Rs $181 million in Q1 FY24. The Company received 6 ANDA approvals from the U.S. FDA and launched 3 products in the quarter in the U.S. India formulation sales for Q1 FY2025 sales were Rs 1,925.9 crore ,up 17.5% compared to Rs 1,638.4 crore in Q1 FY2024; accounting for 35% of Lupin's global sales. India Region Formulation sales grew by 17.4 % in the quarter, as compared to Q4 FY2024; up 10.5% as compared to Q1 FY2024. Growth Markets (LATAM and APAC) registered sales of Rs 515.1 crore during the quarter, up 26.7% as comapred with Rs 406.6 crore in Q1 FY24. EMEA sales for Q1 FY2025 were Rs 5,03.1 crore, registering the growth of 26.2% as comapred with Rs 398.7 crore posted in corresponding quarter last year. Global API sales for Q1 FY2025 were Rs 362.2 crore, up 40.3% compared to Rs 258.1 crore in Q1 FY24, accounting for 7% of Lupin's global sales. Investment in Reasearch & Development (R&D) stood at Rs 350 crore (6.3% of sales) for the quarter compared to Rs 367.9 crore (7.8% of sales) for Q1 FY2024. Nilesh Gupta, managing director, Lupin, said, 'We have had a strong quarter on the back of the momentum we built through FY24, with performance driven by new products, key geographies, and improvement in our operating margin and profitability. We are on track for strong, sustainable growth and margin improvement backed by growth in sales, commercial and operating efficiencies, and a strong compliance story.' Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The scrip hit 52-week high at Rs 2,025 in intraday today.Powered by Capital Market - Live